We know there’s been a lot of recent news about Zantac. On September 13, 2019, Health Canada issued an alert informing Canadians that an impurity had been detected in some ranitidine drugs. Ranitidine is available in Canada over-the-counter (for example, under the brand name Zantac and as generics) and by prescription (as generics).
Health Canada issued a statement requesting that distribution of ranitidine products from all manufacturers be put on hold until testing is done and Health Canada approves that the hold can be lifted. Product currently on shelf can be sold but no further product can be shipped from distributors and retailers to stores and pharmacies. Stock in some stores/pharmacies may soon be depleted and result in Zantac temporarily being unavailable.
At this time, Health Canada is not calling for individuals to stop taking Zantac manufactured by Sanofi Consumer Health in Canada. Longstanding science supports the safety of Zantac, which has been available over-the-counter for over a decade. Health Canada instead recommends that individuals wishing to seek other treatment options should speak to their doctor or pharmacist.
Sanofi Canada takes patient safety and the quality of our products seriously. We are working closely with Health Canada and conducting our own robust internal investigations. At Sanofi, we are committed to being transparent with patients and will continue to share updates as available.
For further information, contact 1-800-636-3664.